The US Court of Appeals for the Federal Circuit concluded on June 18 that Novo Nordisk’s patent covering diabetes treatment repaglinide is invalid.
If you have already subscribed please login.
If you have any technical issues please email tech support.
Novo Nordisk, Caraco, Federal Circuit
